It has been a long tradition for SMi organizing Advances and Progress in Drug Design, that is a high-level, well-organized event. - Dr György Miklós Keserű
London, UK (PRWEB UK) 10 October 2013
SMi Group are proud to announce that registration for the 13th annual Advances and Progress in Drug Design conference is now open.
Advances and Progress in Drug Design 2014 will build on the success of previous events and bring together a unique mix of senior executives from all over industry and academia providing attendees with a forum for problem solving discussion and debate.
Previous installments received positive feedback from the industry including, "Well selected talks, stimulating atmosphere" – Sanofi, "Very good interactive meeting, overall excellent" – Pfizer and "a very good meeting – right number of people" - AstraZeneca
The early bird expires on the 31st October - To book a place and save £300 please, click here.
Dr György Miklós Keserű, Director General from the Research Centre for Natural Sciences in Hungary, who will be speaking at the event recently stated:
“It has been a long tradition for SMi organizing Advances and Progress in Drug Design that is a high-level, well-organized event dedicated to actual challenges and potential solutions of rational drug design. Participants representing both big and mid-pharma companies, biotech organizations, software providers as well as academia enjoy the informal atmosphere of the meeting that provides excellent networking opportunities.”
OTHER SPEAKERS INCLUDE:
John Mathias, Head of Medicinal Chemistry - Inflammation & Remodelling, Pfizer
Sudharsan Sridharan, Scientist, MedImmune
Tom Heightman, Senior Director, Astex Pharmaceuticals
Amaury Ernesto Fernandez-Montalvan, Lab Head, High Throughput Screening, Bayer HealthCare Pharmaceuticals
Karl-Heinz Baringhaus, Site Director, R&D Frankfurt, Sanofi-Aventis
Andreas Kuglstatter, Principle Scientist, Roche Chemische Unternehmungen AG
Dr Neil Press, Director, Novartis
Paul Labute, CEO, Chemical Computing Group
Andrea Bortolato, Senior Computational Chemistry, Heptares Therapeutics
Paul Brennan, Group Head/PI, Nuffield Department of Medicine
Click here to view the full speaker line-up.
Plus attend the two post conference interactive workshops:
Fragment-Based Approach to Lead Discover: Applications and Issues
Workshop Leader: Lee Walmsley, Senior Team Leader, Medicinal Chemistry, Vernalis
08:00 - 12:30 | 19th February 2014, Marriott Regents Park Hotel, London UK
Chemically Modified Biologicals
Workshop Leader: Dr Andrew McElroy, CEO, The Research Network
13:00 - 17:30 | 19th February 2014, Marriott Regents Park Hotel, London UK
The conference will aim to:
- Analyse the pharma industry’s current and future drug design strategies and discuss the challenges the industry is currently facing
- Explore the latest approaches in structure-based drug design
- Evaluate lead optimisation strategies
- Consider the latest in fragment based drug discovery as the future of drug design
- Link HTS and FBDD - examining alternative approaches in drug discovery
- Provide peer to peer networking with two morning coffee breaks, two networking lunches, two afternoon tea sessions and a networking drinks reception hosted by Chemical Computing Group.
Don't miss the chance to become a part of this respected conference series, bringing together academia, KOL’s and leading experts from across the industry. The early bird expires on the 31st October so those interested are advised to register today to save £300.
To book today and for more information please visit, http://www.drug-design.co.uk
Advances and Progress in Drug Design
17th & 18th February
Marriott Regents Park Hotel, London UK